The Blueprint of Medical Research: How New Medicines Get from the Lab to the Patient
Margaret Anderson, Deborah W. Brooks, Anthony Coles, Francis Collins, Margaret Hamburg, Roy A. Jensen, Michael Milken, Ellen V. Sigal
February 6, 2013
"While I can tell you there's never been a more exciting time for science, I can also tell you there's never been a more stressful time," Francis Collins, director of the National Institutes of Health, told this Capitol Hill briefing co-hosted by FasterCures
and Friends of Cancer research The issue at hand? Tightening fiscal resources that threaten the research and development ecosystem to fully deliver science's full potential to improve health and well-being.
Moderated by FasterCures Executive Director Margaret Anderson, Collins, FDA Commissioner Margaret Hamburg and other medical research leaders representing distinct sectors provided a glimpse into what it takes to turn a scientific discovery into a safe and effective therapy that will improve, and maybe even save, patients' lives. More than 300 policymakers, advocates and key legislative staffers participated.
The briefing discussed the vital role federal agencies and the medical research sector play in advancing medical progress. This includes:
The breadth, depth and scope of the research funded by the NIH and how this translates into better health outcomes.
The essential role of the FDA in advancing science and ensuring that patients can access life-saving therapies that are safe and effective.
The distinct roles these federal agencies, industry, academia and patient groups can play on their own, and in collaboration with each other, to speed up the time it takes to get new medicines from the lab to the patient.
Visit our FasterCures center's website for a detailed summary of the briefing.
Margaret Anderson, FasterCures
Deborah W. Brooks, The Michael J. Fox Foundation for Parkinson's Research
N. Anthony Coles, Onyx Pharmaceuticals
Francis Collins, National Institutes of Health
Margaret Hamburg, U.S. Food and Drug Administration
Roy A. Jensen, University of Kansas Cancer Center
Michael Milken, The Milken Institute and FasterCures
Ellen V. Sigal, Friends of Cancer Research